Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
618.00    8.00 (1.31%)
Bid:
615.00
Ask:
618.00
Spread: 3.00 (0.488%)
Market Cap: £747.84m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

2023 AGM Notification

5 May 2023 07:00

RNS Number : 4997Y
Oxford Biomedica PLC
05 May 2023
 

Oxford Biomedica PLC

2023 AGM Notification

London, UK - 5 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "the Company" or "the Group"), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting ("AGM") together with a copy of the 2022 Annual report and accounts are being sent to shareholders today. These documents are available on the "Investors" section of the Group's website at www.oxb.com.

In accordance with Listing rule 9.6.1, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.The Company intends to hold its AGM on Friday 23 June 2023 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

Notes for editors

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUSAKROUUVRAR
Date   Source Headline
7th Oct 20257:00 amRNSAcquisition of US viral vector facility
1st Oct 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSInterim Results for 6 months ended 30 June 2025
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20253:36 pmRNSPDMR Dealings
21st Aug 202510:24 amRNSHolding(s) in Company
20th Aug 20257:00 amRNSAdmission of Shares and Total Voting Rights
15th Aug 20251:45 pmRNSPDMR Dealings
15th Aug 20257:05 amRNSResults of Placing
14th Aug 20255:02 pmRNSProposed Placing of New Ordinary Shares
1st Aug 20257:00 amRNSOXB Secures New Loan Facility with Oaktree
1st Aug 20257:00 amRNSTotal Voting Rights
28th Jul 20257:00 amRNSHalf Year Trading Update
2nd Jul 20257:00 amRNSDirector Declaration
1st Jul 20257:00 amRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTotal Voting Rights
23rd Jun 20257:00 amRNSOXB completes acquisition of US subsidiary
17th Jun 20256:00 pmRNSDirector/PDMR Shareholding
11th Jun 20256:02 pmRNSResult of Annual General Meeting
11th Jun 20257:02 amRNSAGM Update
10th Jun 202510:49 amRNSHolding(s) in Company
5th Jun 20257:00 amRNSBlock Listing Application
3rd Jun 20257:00 amRNS-ROXB Launches Advisory Board
2nd Jun 20257:00 amRNSTotal Voting Rights
16th May 20255:52 pmRNSGrant of options
1st May 20257:00 amRNSTotal Voting Rights
30th Apr 20254:49 pmRNSPerson Closely Associated Dealing
29th Apr 20256:14 pmRNSHolding(s) in Company
28th Apr 20251:00 pmRNS2025 Annual General Meeting notification
23rd Apr 20255:45 pmRNSHolding(s) in Company
9th Apr 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
4th Apr 20258:52 amRNSHolding(s) in Company
1st Apr 20257:00 amRNSOXB Total Voting Rights
27th Mar 20254:45 pmRNSDirector Declaration
3rd Mar 20259:00 amRNSTotal Voting Rights
26th Feb 20257:00 amRNS-ROXB to present at Leerink Conference
20th Feb 20253:42 pmRNSHolding(s) in Company
20th Feb 20251:32 pmRNS-ROXB Lentiviral Vectors Used in Gene Therapy Trial
20th Feb 20251:13 pmRNSStandard form for notification of major holdings
17th Feb 20257:00 amRNSFull Year Trading Update and Notice of Results
5th Feb 20257:00 amRNSAppointment of New Joint Corporate Broker
3rd Feb 20257:00 amRNSTotal Voting Rights
23rd Jan 202511:07 amRNSBlock Listing Application
16th Jan 20254:23 pmRNSHolding(s) in Company
16th Jan 20254:20 pmRNSHolding(s) in Company
15th Jan 20254:30 pmRNSHolding(s) in Company
2nd Jan 20257:00 amRNSBlock Listing Return
2nd Jan 20257:00 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTotal Voting Rights
22nd Nov 20242:56 pmRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.